Antimicrobial Stewardship Program
About the Program
Bacteria and other microorganisms that cause infections are remarkably resilient and can develop ways to survive drugs meant to kill or weaken them. This is known as antibiotic resistance and is due largely to the increasing use of antibiotics.
As a result, if we do not use antibiotics carefully, they will lose their efficacy leading to increased cost, worse healthcare outcomes, and even lost lives. To respond to these challenges, Antimicrobial Stewardship Program (ASP) at CHRISTUS Saint Vincent Regional Medical Center (CHRISTUS SVRMC) was initiated in May 2010.
The ASP is a joint effort of Pharmacy Department, Infectious Diseases, and Infection Control.
The mission of the program is to optimize the utilization of antibiotics in order to improve patient outcomes, patient safety, and have a positive effect on antibiotic resistance.
Antibiotic Management Guideline
Antimicrobial Stewardship Program at Johns Hopkins Hospital has created Antibiotic Management Guidelines that are revised annually. The guidelines are based on current literature reviews, including national guidelines and consensus statements, current microbiologic data from the Johns Hopkins lab, and Hopkins faculty expert opinion.
The guideline should NOT supplant clinical judgment or Infectious Diseases consultation when indicated.
Michael D. Palestine, M.D. – Medical Director. Antimicrobial Stewardship Program
Jasmina Demirovic, Pharm.D., R.Ph. – Associate Director. Antimicrobial Stewardship Program
Michael Lacey, R.Ph. – Pharmacy Director
Patricia Collins, M.T. (ASCP). - Microbiology Section Coordinator
Marsha Meyer, R.N. BSN. CIC. - Infection Prevention Coordinator
Randall Schulz, Ph.D. MLS. (ASCP)cm. - Lab Safety Section Coordinator
Antibiogram - Gram Positive Isolates 2012 - % Susceptible (A)
NR – Not Reported
ND – No Data
A – Data evaluated per Clinical and Laboratory Standards Institute (CLSI) document
B – Enterococcus species include Enterococcus durans and Enterococcus faecalis
C – Use for uncomplicated urinary tract infections only
D – Use for NON-urinary tract infections only
E – Treatment of serious enterococcal infections usually requires therapy with (amp + gent) or (vanco + gent) [if the isolate is susceptible]
F – Penicillin predicts Ampicillin, Cefazolin
G – 12% of total S. pneumo isolates (65) resistant to penicillin
Antibiogram - Gram Negative Isolates 2012 - % Susceptible (A)
ND - No data
NA - Indicates the antibiotic is generally inactive against the particular organism.
A - Data evaluated per Clinical and Laboratory Standards Institute (CLSI) document
B - Use for uncomplicated urinary tract infections only
Treatment of Ps. aeruginosa infections in compromised hosts should include an anti-Pseudomonal beta lactam, to which the isolate is susceptible, in combination with an aminoglycoside, to which the isolate is susceptible.
Aztreonam susceptibility available if called, but will not be reported with laboratory results.